You are here
There are currently more than 30 active launched startups based on the University of Illinois at Chicago IP.
Our portfolio of companies includes:
Developing novel therapeutics that have implications in many conditions, including cancer, Alzheimer’s disease, bipolar disorder, diabetes mellitus type II, and inflammatory conditions leading to fibrosis.
Manufacturing primary cultured cells and cell culture products to provide a broad range of high-quality human and animal primary cells including endothelial, epithelial, tumor and stem cells, along with optimized cell culture media and other related products.
Utilizes satellite-derived imagery combined with ground-based observations to provide crop condition and production information for grain buyers and commodity analysts.
EnteroTrack LLC is developing a capsule that can help identify the presence of esophageal inflammation, leading to faster treatment.
ImmersiveTouch® is a leader in simulation based surgical training and exploration. ImmersiveTouch simulators ‘immerse’ surgeons in a digitally replicated operating environment with high-fidelity 3D virtual anatomies and haptic instrument replicates.
Collecting, interpreting, and structuring web and real-time communications to determine what people are saying about a company and its products and how they are saying it.
Harnessing of the power of human neural stem cells.
Offering data management solutions that allow scientists to store, track, and analyze information for transgenic and knockout mouse colonies, cell and bacterial storage freezers, plasmid constructs and PCR primers.
Triangle Therapeutics develops deoxycytidine kinase (dCK) inhibitors for treatment of Acute Lymphoblastic Leukemia (ALL) and as well as other oncological diseases.
Aurora Microarray Solutions works with researchers and industry to design custom microarray diagnostics and instrumentation from initial concept through data analysis and reporting.
Developing a small peptide based inhibitor into a new type of anti-thrombotic drugs that are more effective in narrowed arteries and less bleeding adverse effect.
A therapeutics company developing a cell-based vaccine treatment for cancer patients with a focus on lung and breast cancer.
Pursuing therapies for breast, ovarian, thyroid, neuroblastoma, and glioblastoma cancers through the use of RNAi (RNA interference or Gene Silencing) techniques.
A medical device company developing highly innovative technology to improve the diagnosis and surgical procedures of patients suffering from stress urinary incontinence (SUI).
Commercializes clinical-grade diagnostic and monitoring medical technologies with an emphasis on technologies that can "recognize and respond" to immediate threats to life-and-limb associated with acute medical emergencies.
A stem cell biotechnolgoy company the is developing treatment for type 1 diabetes.
Advancing drug therapy for the treatment of Tamoxifen-resistant breast cancer.
Developing therapeutics to address the unmet needs of breast cancer patients.